United States Patent 5,641,790: Scope, Claim Construction, and US Patent Landscape for Formula I 55–150 mg Dosage Units

US Patent 5,641,790 centers on a dosage-unit pharmaceutical formulation containing a “compound of formula I” in the amount range of about 55 to about 150 mg per dosage unit, with dependent claim coverage that sweeps in multiple routes of administration and multiple dose strengths. The independent claim is broad on dose-range and compound inclusion (free base, pharmaceutically acceptable salts, and solvates), but narrow in key ways: it is confined to a specific structural “formula I” class and to a defined per-dosage-unit quantity window.

Because the patent’s key variable is the unspecified “compound of formula I” structure (not provided in the prompt as a chemical name or unambiguous structure text), the claim-scope map below is organized around what the claims literally cover: quantity per dosage unit, salt/solvate inclusion, and formulation adaptations for specific therapeutic intentions (bone loss inhibition; serum cholesterol lowering) plus dosage forms (capsule, tablet, suspension) and specific exemplified strengths (60, 75, 100, 125, 150 mg). Patent-landscape conclusions are correspondingly framed at the formulation level (not the exact molecular-entity level).

What does US Patent 5,641,790 claim: what is the core independent claim scope?

Featured snippet answer: Claim 1 claims a pharmaceutical formulation in dosage unit form with 55–150 mg per dosage unit of a compound of formula I, including pharmaceutically acceptable salts or solvates.

Claim 1: literal structure of coverage

Claim 1 reads as follows (paraphrased to operational claim elements):

A pharmaceutical formulation in dosage unit form
Per dosage unit, an amount within about 55 to about 150 mg
Of a compound of formula I
Or a pharmaceutically acceptable salt or solvate of that compound

Practical claim elements for freedom-to-operate (FTO) mapping

Dosage unit form: The claim is not a bulk powder blend or kit unless packaged for discrete dosing. It targets a unit that is measured as one administration unit (tablet, capsule, suspension per dose, etc.).
Dose quantity: The active is constrained to the unit amount range 55–150 mg “about.” Design-around by using lower/higher unit amounts is the most direct quantitative carveout, subject to “about” tolerance and infringement theories.
Active identity: Everything hinges on whether the competitor’s drug substance is within “formula I,” including salt/solvate variants. The claim does not extend to “any cholesterol/bone-loss agent,” only to the Formula I compound(s).

Claim 1: how broad is the “about” range?

The claim uses “about” on both ends, which in US claim construction often allows tolerance around the numerical boundaries. Without the specification text, a precise tolerance cannot be established. Still, as a licensing and litigation posture, the practical implication is:

A generic or competitor should treat 55–150 mg per unit as a zone of heightened infringement risk for the exact Formula I entity and its salts/solvates.
Outside the range (for example 50 mg or 160 mg) reduces direct claim-1 fit but may still raise issues if the accused product is shown to be an insubstantial change or equivalent “about” embodiment, depending on the court’s “about” construction and prosecution history (not provided).

Which dependent claims expand scope: bone loss, serum cholesterol, oral use, and dosage forms?

Featured snippet answer: Claims 2–7 and 4–7 layer functional therapeutic aims (bone loss inhibition; serum cholesterol lowering), administration route (oral), and product form (capsule, tablet, suspension) onto the same dose-amount-independent core of Claim 1.

Claim 2: formulation “adapted for administration to inhibit bone loss”

Requires a formulation adapted for administration for inhibiting bone loss.
This is typically read as a use-adaptation limitation, which can be satisfied by dosage form design and labeling indications, depending on claim interpretation and the asserted infringement theory.

Litigation-relevant implication: even if dose and composition are met, an accused product may attempt to avoid the claim by removing or changing the “adapted for” therapeutic indication (labeling and instructions), while defendants can counter with internal intended use, physician practice, or implied adaptation depending on jurisdiction and case posture.

Claim 3: formulation “adapted for administration to lower serum cholesterol”

Functional/therapeutic intent limitation focused on serum cholesterol reduction.
Same “adapted for” logic as Claim 2.

Claim interaction note: Claims 2 and 3 do not require mutually exclusive indication scope; a single formulation can satisfy both if it is adapted for both outcomes.

Claim 4: oral administration

Limits administration to oral use.
If the product is not orally administered (injectable, transdermal), Claim 4 is harder to satisfy.

Claims 5–7: dosage form

Claim 5: capsule
Claim 6: tablet
Claim 7: suspension

This trio means the patent expects routine solid dosage forms plus liquid oral suspension. It blocks a simple “choose a different oral format” escape route if the competitor’s format still sits within capsule/tablet/suspension.

Design-around angle: If a competitor uses a different oral dosage form (e.g., chewable, orally disintegrating tablet, solution, granules) the literal mapping depends on whether those forms are argued as “adapted for” and whether a court reads them into the claim language. The literal claims are capsule/tablet/suspension, not broadly “oral dosage form,” so exact mapping matters.

How do specific strength claims (60, 75, 100, 125, 150 mg) affect infringement risk?

Featured snippet answer: Claims 8–12 lock in discrete exemplified strengths: 60 mg, 75 mg, 100 mg, 125 mg, 150 mg per dosage unit, each layered onto Claim 1.

Claims 8–12: discrete unit amounts

Claim 8: dosage unit is 60 mg
Claim 9: 75 mg
Claim 10: 100 mg
Claim 11: 125 mg
Claim 12: 150 mg

Key overlap with Claim 1: Each discrete strength falls inside the Claim 1 range (55–150 mg). That means a product matching any of these strengths is highly likely to satisfy both Claim 1 and the respective discrete dependent claim, unless other elements are missing (dose unit form, Formula I definition, salt/solvate inclusion, or therapeutic adaptation limitations).

Commercial implication: If the market standard dosing uses one of these unit strengths, this patent becomes a direct obstacle for generics and for any “authorized generic” that preserves the same unit strengths.

Claim 13: narrower dose band (60–100 mg)

Claim 13 recites dosage unit form with about 60 to about 100 mg per dosage unit of Formula I (or salt/solvate).

This claim is a second independent dose-range “window” (dependent on Claim 1 context by its dependency in the claim set as provided). The key effect is that a product in the middle band (60–100) has multiple claim hooks.

What does “formula I” imply for the patent’s real coverage: compound identity vs. formulation?

Featured snippet answer: The claims do not name the compound structure, but by drafting, they hinge entirely on whether an accused active ingredient is within “compound of formula I,” including salts and solvates.

Where the scope is tight

The patent does not cover:

other actives outside “formula I”
different structural classes that are not encompassed by formula I
non-salt, non-solvate derivatives not within “pharmaceutically acceptable salt or solvate” definitions

Where the scope is broad

The patent covers:

free base and acceptable salts/solvates of the Formula I compound
all dosage forms claimed (capsule, tablet, suspension) if administered orally
multiple therapeutic-adaptation statements (bone loss; serum cholesterol)

Enforcement posture

In practice, formulation-only patents of this type often become “composition of matter adjacent” in litigation when the accused generic uses the same active (or its salt/solvate) at matching unit strengths. The core dispute typically becomes:

Is the accused active within formula I?
Are the accused products within the 55–150 mg per unit range (or the 60–100 mg window)?
Do the accused labels/instructions satisfy the “adapted for” functional limitations?

Because the chemical identity is not supplied in the prompt, no further compound-level narrowing can be responsibly performed.

How long does US 5,641,790 run: when does exclusivity end?

No expiration timeline is provided in the prompt, and US expiration depends on filing date, patent term adjustments, and any terminal disclaimers. The prompt does not include those facts, so an accurate expiration date cannot be produced.

No timeline is provided here.

How many other US patents typically cover the same commercial product: what is the likely landscape around a dosage-unit formulation claim?

Featured snippet answer: A formulation claim with dose-range and route/form limitations is usually one of several layers in a US landscape: active-ingredient patents, salt/solvate patents, method-of-use patents, and later formulation/polymorph/regimen patents. Without the identity of “formula I,” only generic landscape patterns can be stated.

Typical US patent layers around Formula I dosage formulations

Active compound (structure) claims
Coverage of the molecule itself, often broader than formulation claims.
Salt and solvate patents
Coverage for specific salts (e.g., hydrochloride) or solvates (hydrates/ethanolates).
Formulation patents
Dose-ranging claims like this one; excipient systems; tablet/capsule/suspension manufacturing or stability.
Method-of-use patents
Use for bone loss inhibition and for lowering serum cholesterol.
Regimen or dosing frequency patents
Claims on frequency, combination therapy, titration, or persistence.

Litigation and Paragraph IV risk

If the US patent 5,641,790 is listed in the Orange Book for a given NDA/ANDA product (with its active ingredient and dosage form), it can be the basis for a Paragraph IV certification. However, the prompt does not provide Orange Book listing details.

No Paragraph IV filing history is provided here.

What is the Orange Book status of US 5,641,790?

No Orange Book listing details are provided in the prompt. An Orange Book status determination cannot be produced.

Which companies are likely challenging or litigating this patent estate?

No litigation party data or Orange Book/NDA/ANDA linkage is provided in the prompt. Names and case dockets cannot be produced from the information given.

What formulations are protected: does this patent cover tablets, capsules, and suspensions at any excipient system?

Featured snippet answer: Claims 5–7 protect oral capsules, tablets, and suspensions containing Formula I at 55–150 mg per dosage unit (and the specified strengths in dependent claims), without requiring a specific excipient identity in the claim text you provided.

Excipient scope as implied by claim text

Because Claim 1’s elements as provided focus on active amount, dosage unit form, and formula identity, the claim text (as supplied) does not explicitly constrain:

excipient selection
disintegration agents
binders
coating materials
particle size

This generally means infringement risk extends to many excipient variants, as long as the dosage unit matches:

the active identity (formula I; salt/solvate allowed)
the dose per unit range
the dosage form category (capsule/tablet/suspension) and oral administration for the relevant dependent claims
the “adapted for” therapeutic aims for Claims 2–3

How does the dose-range structure drive generic launch scenarios?

Featured snippet answer: The patent creates a quantitative infringement barrier for any generic launch that keeps the same Formula I entity and is dosed in the 55–150 mg per unit range (and especially 60–100 mg, or specific strengths 60/75/100/125/150 mg).

Generic entry risk scenarios

Same unit strength (e.g., 100 mg tablet/capsule)
High risk: matches Claim 1 and Claim 10 directly.
Same therapeutic indication but different dose strength (e.g., 50 mg)
Reduced risk for strict dose-range claim fit, but “about” and equivalency theories can still be asserted.
Different route (not oral)
Avoids Claims 4–7 dependent claim pathways (oral/capsule/tablet/suspension), but Claim 1 could still be asserted unless the product is argued out of “dosage unit form” as construed by the court.
Different dosage form within oral category
Capsule/tablet/suspension are explicitly named. Other oral formats may reduce direct match, but “adapted for” and claim interpretation matter.

How strong is the patent estate for US 5,641,790 specifically: what is defensible in claim construction?

Featured snippet answer: The claim strength is driven by dose-range definiteness and breadth on salts/solvates, but it is constrained by reliance on the undefined “formula I” entity and by therapeutic-adaptation limitations in dependent claims.

Defensibility factors (based on claim text provided)

Clear numeric range (55–150 mg)
Direct inclusion of pharmaceutically acceptable salts and solvates
Explicit dosage forms: capsule, tablet, suspension
Explicit oral administration limitation in Claim 4
Explicit “adapted for” therapeutic purposes in Claims 2 and 3

Vulnerability factors (based on claim text provided)

Narrow around “formula I” identity (not generic)
Dependent therapeutic adaptation terms can become label/intent disputes
Dependent dosage-form terms are exact (capsule/tablet/suspension), limiting reach vs other oral formats

Key Takeaways

US 5,641,790 Claim 1 covers oral dosage-unit formulations containing 55–150 mg per unit of a compound of formula I, including pharmaceutically acceptable salts and solvates.
Claims 2–3 add therapeutic-adaptation limitations for bone loss inhibition and serum cholesterol lowering.
Claims 4–7 restrict dependent coverage to oral administration and specific dosage forms: capsule, tablet, suspension.
Claims 8–12 create high infringement overlap at 60, 75, 100, 125, and 150 mg per unit.
Claim 13 adds a second dose band at about 60–100 mg per unit.
The patent’s practical infringement risk for generics is most acute when the challenger uses the same formula I active (or its acceptable salt/solvate) and markets an oral product in the 55–150 mg per unit range, particularly the discrete strengths enumerated.

FAQs

Does US 5,641,790 cover non-oral routes like injections or implants?
The dependent claims explicitly cover oral administration; Claim 1 as provided does not itself state oral route, but dependent coverage for oral forms is tied to Claims 4–7.
Can a generic avoid infringement by using a lower unit strength than 55 mg?
That is the most direct avoidance for the numeric dose-range limitation, subject to how “about” is construed and whether the product is treated as falling within the range.
If the active is a different salt or solvate of formula I, is it covered?
Yes for “pharmaceutically acceptable salts or solvates” because Claim 1 expressly includes them.
Do labels or indication wording control infringement under Claims 2 and 3?
Those claims use “adapted for administration to inhibit bone loss” and “to lower serum cholesterol,” which in litigation often turns on the product’s labeling and intended use evidence.
Which dosage forms are explicitly covered in the patent claims you provided?
Capsule, tablet, and suspension (Claims 5–7), each in an oral-administration-adapted context (Claim 4).

References

US Patent 5,641,790. (claims text as provided in prompt).

Title:	Methods of use for inhibiting bone loss and lowering serum cholesterol
Abstract:	A method of inhibiting bone loss or resorption, or lowering serum cholesterol, comprising administering to a human in need thereof a compound having the formula ##STR1## or a pharmaceutically acceptable salt or solvate thereof, in a low dosage amount. Also encompased by the invention is a a pharmaceutical formulation in unit dosage form comprising, per unit dosage, a low dosage amount.
Inventor(s):	Michael W. Draper
Assignee:	Eli Lilly and Co
Application Number:	US08/422,417
Patent Claim Types: see list of patent claims	Formulation; Compound; Dosage form;
Patent landscape, scope, and claims:	United States Patent 5,641,790: Scope, Claim Construction, and US Patent Landscape for Formula I 55–150 mg Dosage Units US Patent 5,641,790 centers on a dosage-unit pharmaceutical formulation containing a “compound of formula I” in the amount range of about 55 to about 150 mg per dosage unit, with dependent claim coverage that sweeps in multiple routes of administration and multiple dose strengths. The independent claim is broad on dose-range and compound inclusion (free base, pharmaceutically acceptable salts, and solvates), but narrow in key ways: it is confined to a specific structural “formula I” class and to a defined per-dosage-unit quantity window. Because the patent’s key variable is the unspecified “compound of formula I” structure (not provided in the prompt as a chemical name or unambiguous structure text), the claim-scope map below is organized around what the claims literally cover: quantity per dosage unit, salt/solvate inclusion, and formulation adaptations for specific therapeutic intentions (bone loss inhibition; serum cholesterol lowering) plus dosage forms (capsule, tablet, suspension) and specific exemplified strengths (60, 75, 100, 125, 150 mg). Patent-landscape conclusions are correspondingly framed at the formulation level (not the exact molecular-entity level). What does US Patent 5,641,790 claim: what is the core independent claim scope? Featured snippet answer: Claim 1 claims a pharmaceutical formulation in dosage unit form with 55–150 mg per dosage unit of a compound of formula I, including pharmaceutically acceptable salts or solvates. Claim 1: literal structure of coverage Claim 1 reads as follows (paraphrased to operational claim elements): A pharmaceutical formulation in dosage unit form Per dosage unit, an amount within about 55 to about 150 mg Of a compound of formula I Or a pharmaceutically acceptable salt or solvate of that compound Practical claim elements for freedom-to-operate (FTO) mapping Dosage unit form: The claim is not a bulk powder blend or kit unless packaged for discrete dosing. It targets a unit that is measured as one administration unit (tablet, capsule, suspension per dose, etc.). Dose quantity: The active is constrained to the unit amount range 55–150 mg “about.” Design-around by using lower/higher unit amounts is the most direct quantitative carveout, subject to “about” tolerance and infringement theories. Active identity: Everything hinges on whether the competitor’s drug substance is within “formula I,” including salt/solvate variants. The claim does not extend to “any cholesterol/bone-loss agent,” only to the Formula I compound(s). Claim 1: how broad is the “about” range? The claim uses “about” on both ends, which in US claim construction often allows tolerance around the numerical boundaries. Without the specification text, a precise tolerance cannot be established. Still, as a licensing and litigation posture, the practical implication is: A generic or competitor should treat 55–150 mg per unit as a zone of heightened infringement risk for the exact Formula I entity and its salts/solvates. Outside the range (for example 50 mg or 160 mg) reduces direct claim-1 fit but may still raise issues if the accused product is shown to be an insubstantial change or equivalent “about” embodiment, depending on the court’s “about” construction and prosecution history (not provided). Which dependent claims expand scope: bone loss, serum cholesterol, oral use, and dosage forms? Featured snippet answer: Claims 2–7 and 4–7 layer functional therapeutic aims (bone loss inhibition; serum cholesterol lowering), administration route (oral), and product form (capsule, tablet, suspension) onto the same dose-amount-independent core of Claim 1. Claim 2: formulation “adapted for administration to inhibit bone loss” Requires a formulation adapted for administration for inhibiting bone loss. This is typically read as a use-adaptation limitation, which can be satisfied by dosage form design and labeling indications, depending on claim interpretation and the asserted infringement theory. Litigation-relevant implication: even if dose and composition are met, an accused product may attempt to avoid the claim by removing or changing the “adapted for” therapeutic indication (labeling and instructions), while defendants can counter with internal intended use, physician practice, or implied adaptation depending on jurisdiction and case posture. Claim 3: formulation “adapted for administration to lower serum cholesterol” Functional/therapeutic intent limitation focused on serum cholesterol reduction. Same “adapted for” logic as Claim 2. Claim interaction note: Claims 2 and 3 do not require mutually exclusive indication scope; a single formulation can satisfy both if it is adapted for both outcomes. Claim 4: oral administration Limits administration to oral use. If the product is not orally administered (injectable, transdermal), Claim 4 is harder to satisfy. Claims 5–7: dosage form Claim 5: capsule Claim 6: tablet Claim 7: suspension This trio means the patent expects routine solid dosage forms plus liquid oral suspension. It blocks a simple “choose a different oral format” escape route if the competitor’s format still sits within capsule/tablet/suspension. Design-around angle: If a competitor uses a different oral dosage form (e.g., chewable, orally disintegrating tablet, solution, granules) the literal mapping depends on whether those forms are argued as “adapted for” and whether a court reads them into the claim language. The literal claims are capsule/tablet/suspension, not broadly “oral dosage form,” so exact mapping matters. How do specific strength claims (60, 75, 100, 125, 150 mg) affect infringement risk? Featured snippet answer: Claims 8–12 lock in discrete exemplified strengths: 60 mg, 75 mg, 100 mg, 125 mg, 150 mg per dosage unit, each layered onto Claim 1. Claims 8–12: discrete unit amounts Claim 8: dosage unit is 60 mg Claim 9: 75 mg Claim 10: 100 mg Claim 11: 125 mg Claim 12: 150 mg Key overlap with Claim 1: Each discrete strength falls inside the Claim 1 range (55–150 mg). That means a product matching any of these strengths is highly likely to satisfy both Claim 1 and the respective discrete dependent claim, unless other elements are missing (dose unit form, Formula I definition, salt/solvate inclusion, or therapeutic adaptation limitations). Commercial implication: If the market standard dosing uses one of these unit strengths, this patent becomes a direct obstacle for generics and for any “authorized generic” that preserves the same unit strengths. Claim 13: narrower dose band (60–100 mg) Claim 13 recites dosage unit form with about 60 to about 100 mg per dosage unit of Formula I (or salt/solvate). This claim is a second independent dose-range “window” (dependent on Claim 1 context by its dependency in the claim set as provided). The key effect is that a product in the middle band (60–100) has multiple claim hooks. What does “formula I” imply for the patent’s real coverage: compound identity vs. formulation? Featured snippet answer: The claims do not name the compound structure, but by drafting, they hinge entirely on whether an accused active ingredient is within “compound of formula I,” including salts and solvates. Where the scope is tight The patent does not cover: other actives outside “formula I” different structural classes that are not encompassed by formula I non-salt, non-solvate derivatives not within “pharmaceutically acceptable salt or solvate” definitions Where the scope is broad The patent covers: free base and acceptable salts/solvates of the Formula I compound all dosage forms claimed (capsule, tablet, suspension) if administered orally multiple therapeutic-adaptation statements (bone loss; serum cholesterol) Enforcement posture In practice, formulation-only patents of this type often become “composition of matter adjacent” in litigation when the accused generic uses the same active (or its salt/solvate) at matching unit strengths. The core dispute typically becomes: Is the accused active within formula I? Are the accused products within the 55–150 mg per unit range (or the 60–100 mg window)? Do the accused labels/instructions satisfy the “adapted for” functional limitations? Because the chemical identity is not supplied in the prompt, no further compound-level narrowing can be responsibly performed. How long does US 5,641,790 run: when does exclusivity end? No expiration timeline is provided in the prompt, and US expiration depends on filing date, patent term adjustments, and any terminal disclaimers. The prompt does not include those facts, so an accurate expiration date cannot be produced. No timeline is provided here. How many other US patents typically cover the same commercial product: what is the likely landscape around a dosage-unit formulation claim? Featured snippet answer: A formulation claim with dose-range and route/form limitations is usually one of several layers in a US landscape: active-ingredient patents, salt/solvate patents, method-of-use patents, and later formulation/polymorph/regimen patents. Without the identity of “formula I,” only generic landscape patterns can be stated. Typical US patent layers around Formula I dosage formulations Active compound (structure) claims Coverage of the molecule itself, often broader than formulation claims. Salt and solvate patents Coverage for specific salts (e.g., hydrochloride) or solvates (hydrates/ethanolates). Formulation patents Dose-ranging claims like this one; excipient systems; tablet/capsule/suspension manufacturing or stability. Method-of-use patents Use for bone loss inhibition and for lowering serum cholesterol. Regimen or dosing frequency patents Claims on frequency, combination therapy, titration, or persistence. Litigation and Paragraph IV risk If the US patent 5,641,790 is listed in the Orange Book for a given NDA/ANDA product (with its active ingredient and dosage form), it can be the basis for a Paragraph IV certification. However, the prompt does not provide Orange Book listing details. No Paragraph IV filing history is provided here. What is the Orange Book status of US 5,641,790? No Orange Book listing details are provided in the prompt. An Orange Book status determination cannot be produced. Which companies are likely challenging or litigating this patent estate? No litigation party data or Orange Book/NDA/ANDA linkage is provided in the prompt. Names and case dockets cannot be produced from the information given. What formulations are protected: does this patent cover tablets, capsules, and suspensions at any excipient system? Featured snippet answer: Claims 5–7 protect oral capsules, tablets, and suspensions containing Formula I at 55–150 mg per dosage unit (and the specified strengths in dependent claims), without requiring a specific excipient identity in the claim text you provided. Excipient scope as implied by claim text Because Claim 1’s elements as provided focus on active amount, dosage unit form, and formula identity, the claim text (as supplied) does not explicitly constrain: excipient selection disintegration agents binders coating materials particle size This generally means infringement risk extends to many excipient variants, as long as the dosage unit matches: the active identity (formula I; salt/solvate allowed) the dose per unit range the dosage form category (capsule/tablet/suspension) and oral administration for the relevant dependent claims the “adapted for” therapeutic aims for Claims 2–3 How does the dose-range structure drive generic launch scenarios? Featured snippet answer: The patent creates a quantitative infringement barrier for any generic launch that keeps the same Formula I entity and is dosed in the 55–150 mg per unit range (and especially 60–100 mg, or specific strengths 60/75/100/125/150 mg). Generic entry risk scenarios Same unit strength (e.g., 100 mg tablet/capsule) High risk: matches Claim 1 and Claim 10 directly. Same therapeutic indication but different dose strength (e.g., 50 mg) Reduced risk for strict dose-range claim fit, but “about” and equivalency theories can still be asserted. Different route (not oral) Avoids Claims 4–7 dependent claim pathways (oral/capsule/tablet/suspension), but Claim 1 could still be asserted unless the product is argued out of “dosage unit form” as construed by the court. Different dosage form within oral category Capsule/tablet/suspension are explicitly named. Other oral formats may reduce direct match, but “adapted for” and claim interpretation matter. How strong is the patent estate for US 5,641,790 specifically: what is defensible in claim construction? Featured snippet answer: The claim strength is driven by dose-range definiteness and breadth on salts/solvates, but it is constrained by reliance on the undefined “formula I” entity and by therapeutic-adaptation limitations in dependent claims. Defensibility factors (based on claim text provided) Clear numeric range (55–150 mg) Direct inclusion of pharmaceutically acceptable salts and solvates Explicit dosage forms: capsule, tablet, suspension Explicit oral administration limitation in Claim 4 Explicit “adapted for” therapeutic purposes in Claims 2 and 3 Vulnerability factors (based on claim text provided) Narrow around “formula I” identity (not generic) Dependent therapeutic adaptation terms can become label/intent disputes Dependent dosage-form terms are exact (capsule/tablet/suspension), limiting reach vs other oral formats Key Takeaways US 5,641,790 Claim 1 covers oral dosage-unit formulations containing 55–150 mg per unit of a compound of formula I, including pharmaceutically acceptable salts and solvates. Claims 2–3 add therapeutic-adaptation limitations for bone loss inhibition and serum cholesterol lowering. Claims 4–7 restrict dependent coverage to oral administration and specific dosage forms: capsule, tablet, suspension. Claims 8–12 create high infringement overlap at 60, 75, 100, 125, and 150 mg per unit. Claim 13 adds a second dose band at about 60–100 mg per unit. The patent’s practical infringement risk for generics is most acute when the challenger uses the same formula I active (or its acceptable salt/solvate) and markets an oral product in the 55–150 mg per unit range, particularly the discrete strengths enumerated. FAQs Does US 5,641,790 cover non-oral routes like injections or implants? The dependent claims explicitly cover oral administration; Claim 1 as provided does not itself state oral route, but dependent coverage for oral forms is tied to Claims 4–7. Can a generic avoid infringement by using a lower unit strength than 55 mg? That is the most direct avoidance for the numeric dose-range limitation, subject to how “about” is construed and whether the product is treated as falling within the range. If the active is a different salt or solvate of formula I, is it covered? Yes for “pharmaceutically acceptable salts or solvates” because Claim 1 expressly includes them. Do labels or indication wording control infringement under Claims 2 and 3? Those claims use “adapted for administration to inhibit bone loss” and “to lower serum cholesterol,” which in litigation often turns on the product’s labeling and intended use evidence. Which dosage forms are explicitly covered in the patent claims you provided? Capsule, tablet, and suspension (Claims 5–7), each in an oral-administration-adapted context (Claim 4). References US Patent 5,641,790. (claims text as provided in prompt). More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	1355195	⤷ Start Trial
Australia	702575	⤷ Start Trial
Brazil	9500784	⤷ Start Trial
Canada	2141999	⤷ Start Trial
China	1119530	⤷ Start Trial
Colombia	4340681	⤷ Start Trial
Czech Republic	9500313	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,641,790

Summary for Patent: 5,641,790